Table 2.
Particle size, polydispersity (PDI), zeta potential (ZP), nanoparticle concentration (NC), encapsulation efficiency (%EE) and drug loading capacity (%DL) of the optimized NLC formulations (mean ± SD, n = 3).
| Formulation | Size (nm) | PDI | ZP (mV) | NC (× 1013/mL) | %EE | %DL | |
|---|---|---|---|---|---|---|---|
| CP-TRANS | 166.6 ± 1.4 | 0.115 ± 0.031 | − 17.4 ± 0.6 | 7.81 ± 0.43 | – | ||
| CP-TRANS/TTC | 199.0 ± 2.5 | 0.187 ± 0.028 | − 21.8 ± 1.5 | 7.77 ± 0.19 | 68.1 ± 3.5 | 11.1 ± 0.2 | |
| CP-DK | 189.9 ± 2.9 | 0.112 ± 0.015 | − 19.0 ± 0.9 | 11.50 ± 0.34 | – | ||
| CP-DK/TTC | 215.8 ± 1.8 | 0.172 ± 0.010 | − 27.8 ± 0.5 | 9.20 ± 0.98 | 65.0 ± 2.5 | 11.6 ± 0.4 | |
| MM-DK | 193.3 ± 2.7 | 0.139 ± 0.021 | − 29.0 ± 1.7 | 10.80 ± 0.33 | – | ||
| MM-DK/TTC | 222.2 ± 2.6 | 0.154 ± 0.020 | − 30.1 ± 0.3 | 6.77 ± 0.48 | 63.7 ± 4.2 | 11.6 ± 0.8 | |